AKAP1 Protects Retinal Ganglion Cells and Preserves Vision by Improving Mitochondrial and Synaptic Health in Glaucomatous Neurodegeneration.
4 affiliations
- 1Viterbi Family Department of Ophthalmology, Viterbi Family Vision Research Center, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.
- 2National Center for Microscopy and Imaging Research, Department of Neurosciences, University of California San Diego, La Jolla, California, USA.
- 3Department of Medicine, University of California San Diego, La Jolla, California, USA.
- 4Institute of Engineering in Medicine, Shu Chien - Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, California, USA.
Abstract
Glaucoma, a leading cause of irreversible blindness, is characterized by progressive loss of retinal ganglion cells (RGCs) and lacks effective neuroprotective therapies. Despite evidence implicating mitochondrial dysfunction in glaucoma, the mechanisms linking elevated intraocular pressure, synaptic dysfunction, mitochondrial failure, and RGC death remain incompletely understood. Here we identify the mitochondrial scaffold protein A-kinase anchoring protein 1 (AKAP1) as a critical regulator of RGC resilience in glaucoma. AKAP1 expression is reduced in glaucomatous retinas and correlates with disrupted mitochondrial dynamics, oxidative stress, synaptic impairment, and visual decline. AAV2-mediated restoration of AKAP1 preserves RGC survival and visual function in two independent experimental glaucoma models. These data suggest that retinal AKAP1 promotes mitochondrial fusion, cristae integrity, and bioenergetic capacity in the inner retina and in stressed cultured RGCs, and is accompanied by increased mitochondrial content in presynaptic terminals of the inner plexiform layer. Retinal AKAP1 is further associated with higher PKA abundance, normalized CaMKII and synapsin phosphorylation, preserved synaptophysin, and lower complement C1q and glial activation markers; these associations do not, by themselves, establish causality. These findings identify AKAP1 as a candidate regulator of mitochondrial and synaptic homeostasis and highlight AAV2-AKAP1 gene therapy as a promising neuroprotective strategy for vision preservation in glaucoma.
Related
- Therapeutic Targeting of the LXR Pathway for Improving Myelin Integrity in Neurodegeneration
- Epigallocatechin-3-gallate attenuates PAR-2–mediated inflammatory signaling and preserves markers of mitochondrial integrity in osteoarthritic chondrocytes
- Chicoric acid-rich extract of Cichorium intybus seeds (CAREOCI) preserves pancreatic β-cell function under glucotoxic stress through modulation of MAFA, DYRK1A, cell cycle, apoptosis, and mitochondrial dysfunction
- Adipocyte-specific mitochondrial intermediate peptidase (Mipep) deficiency protects against LPS-induced lethal inflammation through GDF15- and FGF21-independent mechanisms
- Ischemic Postconditioning Protects Aged Myocardium Against Ischemia/Reperfusion Injury by Regulating Mitochondrial Dynamics via piR-4913.
BibTeX
@article{bastola2026akap1,
title = {{AKAP1 Protects Retinal Ganglion Cells and Preserves Vision by Improving Mitochondrial and Synaptic Health in Glaucomatous Neurodegeneration.}},
author = {Tonking Bastola and Keun-Young Kim and Ziyao Shen and Guy A Perkins and Muna Poudel and Yoonjin Lim and Hyejeong Choi and Soo-Ho Choi and Mark H Ellisman and Robert N Weinreb and Won-Kyu Ju},
journal = {Advanced science (Weinheim, Baden-Wurttemberg, Germany)},
year = {2026},
month = oct,
doi = {10.1002/advs.78349},
url = {https://europepmc.org/article/MED/42893477},
note = {CC BY},
}
RIS
TY - JOUR
TI - AKAP1 Protects Retinal Ganglion Cells and Preserves Vision by Improving Mitochondrial and Synaptic Health in Glaucomatous Neurodegeneration.
AU - Tonking Bastola
AU - Keun-Young Kim
AU - Ziyao Shen
AU - Guy A Perkins
AU - Muna Poudel
AU - Yoonjin Lim
AU - Hyejeong Choi
AU - Soo-Ho Choi
AU - Mark H Ellisman
AU - Robert N Weinreb
AU - Won-Kyu Ju
PY - 2026
DA - 2026/10/18
JO - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
DO - 10.1002/advs.78349
UR - https://europepmc.org/article/MED/42893477
AB - Glaucoma, a leading cause of irreversible blindness, is characterized by progressive loss of retinal ganglion cells (RGCs) and lacks effective neuroprotective therapies. Despite evidence implicating mitochondrial dysfunction in glaucoma, the mechanisms linking elevated intraocular pressure, synaptic dysfunction, mitochondrial failure, and RGC death remain incompletely understood. Here we identify the mitochondrial scaffold protein A-kinase anchoring protein 1 (AKAP1) as a critical regulator of RGC resilience in glaucoma. AKAP1 expression is reduced in glaucomatous retinas and correlates with disrupted mitochondrial dynamics, oxidative stress, synaptic impairment, and visual decline. AAV2-mediated restoration of AKAP1 preserves RGC survival and visual function in two independent experimental glaucoma models. These data suggest that retinal AKAP1 promotes mitochondrial fusion, cristae integrity, and bioenergetic capacity in the inner retina and in stressed cultured RGCs, and is accompanied by increased mitochondrial content in presynaptic terminals of the inner plexiform layer. Retinal AKAP1 is further associated with higher PKA abundance, normalized CaMKII and synapsin phosphorylation, preserved synaptophysin, and lower complement C1q and glial activation markers; these associations do not, by themselves, establish causality. These findings identify AKAP1 as a candidate regulator of mitochondrial and synaptic homeostasis and highlight AAV2-AKAP1 gene therapy as a promising neuroprotective strategy for vision preservation in glaucoma.
SN - 2198-3844
ER -